A Laboratory-Friendly CTC Identification: Comparable Double-Immunocytochemistry with Triple-Immunofluorescence.
CTC
immunocytochemistry
laboratory-friendly
parallel double-detection
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jun 2022
10 Jun 2022
Historique:
received:
25
05
2022
revised:
03
06
2022
accepted:
05
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
The source of circulating tumor cells (CTC) in the peripheral blood of patients with solid tumors are from primary cancer, metastatic sites, and a disseminated tumor cell pool. As 90% of cancer-related deaths are caused by metastatic progression and/or resistance-associated treatment failure, the above fact justifies the undeniable predictive and prognostic value of identifying CTC in the bloodstream at stages of the disease progression and resistance to treatment. Yet enumeration of CTC remains far from a standard routine procedure either for post-surgery follow-ups or ongoing adjuvant therapy. The most compelling explanation for this paradox is the absence of a convenient, laboratory-friendly, and cost-effective method to determine CTC. We presented a specific and sensitive laboratory-friendly
Identifiants
pubmed: 35740537
pii: cancers14122871
doi: 10.3390/cancers14122871
pmc: PMC9221448
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Avera McKennan Hospital & University Health Center
ID : NA
Références
Expert Rev Mol Diagn. 2018 Feb;18(2):155-163
pubmed: 29319382
Expert Rev Anticancer Ther. 2019 Dec;19(12):1077-1088
pubmed: 31778322
RSC Adv. 2014;9:4334-4342
pubmed: 25614802
Ann Gastroenterol Surg. 2017 Apr 25;1(1):60-68
pubmed: 29863113
Clin Cancer Res. 2018 Sep 15;24(18):4437-4443
pubmed: 29567812
Methods Mol Biol. 2021;2195:245-261
pubmed: 32852768
Pathol Oncol Res. 2020 Oct;26(4):2435-2442
pubmed: 32557169
J Clin Oncol. 2012 Nov 1;30(31):3819-26
pubmed: 23008288
Cytometry A. 2015 Feb;87(2):137-44
pubmed: 25515318
Mol Oncol. 2016 Mar;10(3):418-30
pubmed: 26809472
Int J Clin Oncol. 2017 Jun;22(3):421-430
pubmed: 28238187
Nat Commun. 2020 Jan 27;11(1):525
pubmed: 31988276
Cells. 2019 Aug 27;8(9):
pubmed: 31461978
Methods Mol Biol. 2017;1572:511-524
pubmed: 28299708
Ann Oncol. 2012 Sep;23(9):2352-2356
pubmed: 22351740
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Clin Cancer Res. 2012 Oct 15;18(20):5711-8
pubmed: 23014524
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3514-9
pubmed: 24550495
Sci Transl Med. 2017 Aug 16;9(403):
pubmed: 28814544
Clin Cancer Res. 2002 May;8(5):1085-91
pubmed: 12006523
Nat Med. 2014 Dec;20(12):1472-8
pubmed: 25326804
Adv Exp Med Biol. 2016;882:235-58
pubmed: 26987538
Clin Cancer Res. 2014 May 15;20(10):2553-68
pubmed: 24831278
AJR Am J Roentgenol. 2019 Jul;213(1):W1-W8
pubmed: 30973775
PLoS One. 2015 Jul 17;10(7):e0132901
pubmed: 26186556
BMC Cancer. 2016 May 06;16:300
pubmed: 27150191
Cancer Commun (Lond). 2019 Jan 3;39(1):1
pubmed: 30606259
Mol Oncol. 2021 Jun;15(6):1647-1666
pubmed: 33289351
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Adv Exp Med Biol. 2020;1220:93-115
pubmed: 32304082